|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jomrich G and Schoppmann SF: Targeted
therapy in gastric cancer. Eur Surg. 48:278–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartley AN, Washington MK, Colasacco C,
Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D,
Kakar S, et al: HER2 testing and clinical decisions making in
gastroesophageal adenocarcinoma: Guideline from the College of
American Pahologists, American Society for Clinical Pathology, and
the American Society of Clinical Oncology. J Clin Oncol.
35:446–464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abrahao-Machado LF and Scapulatempo-Neto
C: HER2 testing in gastric cancer: An update. World J
Gastroenterol. 22:4619–4625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rüschoff J, Dietel M, Barreton G, Arbogast
S, Walch A, Monges G, Chenard M-P, Panault-LLorca F, Nagelmeier I,
Schlake W, et al: HER2 diagnostics in gastric cancer-guideline
validation and development of standardized immunohistochemical
testing. Virchows Arch. 457:299–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baretton G, Kreipe HH, Schirmacher P,
Gaiser T, Hofheinz R, Berghäuser KH, Koch W, Künzel C, Morris S and
Rüschoff J; Nicht-interventionelle Untersuchung (NIU) HER2 Study
Group, : HER2 testing in gastric cancer diagnosis: Insights on
variables influencing HER2-positivity from a large, multicenter,
observational study in Germany. Virchows Arch. 474:551–560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B,
Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M and Mohammed
M: Clinical array-based karyotyping of breast cancer with equivocal
HER2 status resolves gene copy number and reveals chromosome 17
complexity. BMC Cancer. 10:396–404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanna WM, Rüschoff J, Bilous M, Coudry RA,
Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M and Viale
G: HER2 in situ hybridization in breast cancer: Clinical
implications of polysomy 17 and genetic heterogeneity. Mod Pathol.
27:4–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim A, Shin HC, Bae YK, Kim MK, Kang SH,
Lee SJ and Lee EH: Multiplication of chromosome 17 centromere is
associated with prognosis in patients with invasive breast cancer
exhibiting normal HER2 and TOP2A status. J Breast Cancer. 15:24–33.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee K, Jang MH, Chung YR, Lee Y, Kang E,
Kim S-W, Kim YJ, Kim JH, Kim IA and Park SY: Prognostic
significance of centromere 17 copy number gain in breast cancer
depends on breast cancer subtype. Hum Pathol. 61:111–120. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ciesielski M, Kruszewski WJ, Śmiałek U,
Walczak J, Szajewski M, Szefel J, Wydra J and Kawecki K: The HER2
gene and HER2 protein status and chromosome 17 polysomy in gastric
cancer cells in own material. Appl Immunohistochem Mol Morphol.
23:113–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene F and Trotti A: American Joint Committee on Cancer, American
Cancer Society, AJCC Cancer Staging Manual. 7th edition. Springer;
New York, NY: 2010
|
|
15
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Degiuli M, De Manzoni G, Di Leo A, D'Ugo
D, Galasso E, Marrelli D, Petrioli R, Połom K, Roviello F, Santullo
F and Morino M: Gastric cancer: Current status of lymph node
dissection. World J Gastroenterol. 22:2875–2893. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gomez-Martin C, Plaza JC, Pazo-Cid R,
Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, et
al: Level of HER2 gene amplification predicts response and overall
survival in HER2-positive advanced gastric cancer treated with
trastuzumab. J Clin Oncol. 31:4445–4452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McLean MH and El-Omar EM: Genetics of
gastric cancer. Nat Rev Gastroenterol Hepatol. 11:664–674. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshida H, Yamamoto N, Taniguchi H, Oda I,
Katai H, Kushima R and Tsuda H: Comparison of HER2 status between
surgically resected specimens and matched biopsy specimens of
gastric intestinal-type adenocarcinoma. Virchows Arch. 465:145–154.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grabsch H, Sivakumar S, Gray S, Gabbert HE
and Müller W: HER2 expression in gastric cancer: Rare,
heterogeneous and of no prognostic value-conclusions from 924 cases
of two independent series. Cell Oncol. 32:57–65. 2010.PubMed/NCBI
|
|
21
|
Van Cutsem E, Bang YJ, Feng-yi F, Xu JM,
Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et
al: HER2 screening data from TOGA: Targeting HER2 in gastric and
gastroesophageal junction cancer. Gastric Cancer. 18:476–484. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang T, Amemiya Y, Henry P, Seth A, Hanna
W and Hsieh ET: Multiplex ligation-dependent probe amplification
can clarify HER2 status in gastric cancer with ‘polysomy 17’. J
Cancer. 6:403–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeh IT, Martin MA, Robetorye RS, Bolla AR,
McCaskill C, Shah RK, Gorre ME, Mohammed MS and Gunn SR: Clinical
validation of an array CGH test for HER2 status in breast cancer
reveals that polysomy 17 is a rare event. Mod Pathol. 22:1169–1175.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanguedolce F and Bufo P: HER2 assessment
by silver in situ hybridization: Where are we now? Expert Rev Mol
Diagn. 15:385–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koudelakova V, Trojanec R, Vrbkova J,
Donevska S, Bouchalova K, Kolar Z, Varanasi L and Hajduch M:
Frequency of chromosome 17 polysomy in relation to CEP17 copy
number in a large breast cancer cohort. Genes Chromosomes Cancer.
55:409–417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marchiò C, Lambros MB, Gugliotta P, Di
Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber
N, et al: Does chromosome 17 centromere copy number predict
polysomy in breast cancer? A fluorescence in situ hybridization and
microarray-based CGH analysis. J Pathol. 219:16–24. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moelans CB, de Weger RA and van Diest PJ:
Absence of chromosome 17 polysomy in breast cancer: Analysis by
CEP17 chromogenic in situ hybridization and multiplex
ligation-dependent probe amplification. Breast Cancer Res Treat.
120:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A,
Kradolfer D, Bosshard G, Jochum W, Moch H and Öhlschlegel C:
Co-amplification of the HER2 gene and chromosome 17 centromere: A
potential diagnostic pitfall in HER2 testing in breast cancer.
Breast Cancer Res Treat. 132:925–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu FP, Wang K, Xu J, Chen J, Zhang YF, Wu
HM, Zhang MH, Long XX, Luo XL, Zhang KP, et al: Impact of repeat
HER2 testing after initial equivocal HER2 FISH results using 2013
ASCO/CAP guidelines. Breast Cancer Res Treat. 166:757–764. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Onchi H, Hirose K, Yamaguchi A, Noriki S
and Fukuda M: Prognostic value of numerical aberrations of
chromosome 17 in differentiated gastric cancer: Evaluation by
multivariate regression analysis. Oncol Rep. 7:1317–1322.
2000.PubMed/NCBI
|
|
31
|
Krishnamurti U, Hammers JL, Atem FD,
Storto PD and Silverman JF: Poor prognostic significance of
unamplified chromosome 17 polysomy in invasive breast carcinoma.
Mod Pathol. 22:1044–1048. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orsaria M, Khelifa S, Buza N, Kamath A and
Hui P: Chromosome 17 polysomy: Correlation with histological
parameters and HER2NEU gene amplification. J Clin Pathol.
66:1070–1075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hofmann M, Stoss O, Gaiser T, Kneitz H,
Heinmöller P, Gutjahr T, Kaufmann M, Henkel T and Rüschoff J:
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin)
phase II monotherapy study: Assessment of test sensitivity and
impact of chromosome 17 polysomy. J Clin Pathol. 61:89–94. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaufman PA, Broadwater G, Lezon-Geyda K,
Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ,
Seidman AD and Harris LN: Correlation of HER2 and chromosome 17
(ch17) copy number with trastuzumab (T) efficacy in CALGB 9840,
paclitaxel (P) with or without T in HER2+ and
HER2− metastatic breast cancer (MBC). J Clin Oncol.
25:10092007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reinholz MM, Bruzek AK, Visscher DW,
Lingle WL, Schroeder MJ, Perez EA and Jenkins RB: Breast cancer and
aneusomy 17: Implications for carcinogenesis and therapeutic
response. Lancet Oncol. 10:267–277. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar : PubMed/NCBI
|
